Respiratory syncytial virus disease: Update on treatment and prevention

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 1, 2011, Pages 27-32

  Krilov, Leonard R ^a,b  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

bronchiolitis; motavizumab; palivizumab; ribavirin; RSV

Indexed keywords

ADRENALIN; CORTICOSTEROID; MONTELUKAST; MOTAVIZUMAB; PALIVIZUMAB; PLACEBO; RIBAVIRIN; SALBUTAMOL; SMALL INTERFERING RNA;

ACUTE DISEASE; BRONCHIOLITIS; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HIGH RISK INFANT; HUMAN; INFECTION PREVENTION; LENGTH OF STAY; LOWER RESPIRATORY TRACT INFECTION; NONHUMAN; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; SINGLE DRUG DOSE; SKIN MANIFESTATION; TREATMENT DURATION; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; BRONCHIOLITIS, VIRAL; BRONCHODILATOR AGENTS; CHILD; CLINICAL TRIALS AS TOPIC; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RESPIRATORY TRACT INFECTIONS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 78650656135     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.140     Document Type: Review

References (48)

1. Morris JA, Blant RE Jr, Savage RE. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc. Soc. Exp. Bio. Med. 92, 544-550 (1956).
2. Chanock R, Finberg L. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza (CCA). II. Epidemiologic aspects of infection in infants and young children. Am. J. Hyg. 66, 291-300 (1957).
3. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med. 360, 588-598 (2009).
4. Shay DK, Holman RC, Newman RD, et al. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 282, 1440-1446 (1999).
5. Howard TS, Hoffman LH, Stang PE, Simoes EA. Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges, and mortality. J. Pediatr. 137, 227-232 (2000).
6. Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J. Pediatr. 14, S127-S132 (2003).
7. Boyce TG, Mellen BG, Mitchel EF Jr, et al. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J. Pediatr. 137, 865-870 (2000).
8. Law BJ, MacDonald NE, Langley JM, et al. Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: what are we trying to prevent? J. Paediatr. Child Health 3(6), 402-404 (1998).
9. Falsey AR, Hennessey PA, Formica MA, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352, 1749-1759 (2005).
10. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289, 227-229 (2003).
11. Sigurs N, Gustafsson PM, Bjarnason R, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am. J. Respir. Crit. Care Med. 171, 137-141 (2005).
12. Stein RT, Sherril D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 354, 541-545 (1999).
13. Taussig LM, Wright AL, Holberg CJ, et al. Tuscon childrens respiratory study 1980 to present. J. Allergy Clin. Immunol. 111, 661-675 (2003).
14. Collins PL, Channock RM, Murphy BR. Respiratory syncytial virus. In: Fields Virology. Knipe DM, Howley PM, et al. (Eds). Lippincott Williams & Wilkins, Philadelphia, PA, USA, 1443-1485 (2001).
15. Hall CB, Walsh EE, Schnabel KC, et al. Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J. Infect. Dis. 162, 1283-1290 (1990).
16. Subcommittee on diagnosis and management of bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics 118, 1774-1793 (2006).
17. Gadomski AM, Bhasale AL. Bronchodilators for bronchiolitis. Cochrane Database Syst. Rev. 3, CD001266 (2009).
18. Flores G, Horwitz RI. Efficacy of b2 agonists in bronchiolitis: a reappraisal and metaanalysis. Pediatrics 100, 233-239 (1997).
19. Patel H, Gouin S, Platt RW. Randomized, double-blind, placebo-controlled trial of oral albuterol in infants with mild-to-moderate acute viral bronchiolits. J. Pediatr. 142, 509-514 (2003).
20. Schuh S, Canny G, Reismann JJ, et al. Nebulized albuterol in acute bronchiolitis. J. Pediatr. 117, 633-637 (1990).
21. Gadomski AM, Lichenstein R, Horton L, et al. Efficacy of albuterol in the management of bronchiolitis. Pediatrics 93, 907-912 (1994).
22. Hartling L, Wiebe N, Russell K, et al. Epinephrine for bronchiolitis. Cochrane Database Syst. Rev. 1, CD003123 (2004).
23. Wainwright C, Altamirano L, Cheney M, et al. A multicenter, randomized, double-blind, controlled trial of nebulized epinephrine in infants with acute bronchiolitis. N. Engl. J. Med. 349, 27-35 (2003).
24. Menon K, Sutcliffe T, Klassen TP. A randomized trial comparing the efficacy of epinephrine with salbutamol in the treatment of acute bronchiolits. J. Pediatr. 126, 1004-1007 (1995).
25. Corneli HM, Zorc JJ, Majahan P, et al. A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis. N. Engl. J. Med. 357, 331-339 (2007).
26. Patel H, Platt R, Lozano JM, Wang EEL. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Dtabase Syst. Rev. 4, 1-63 (2004).
27. Amirav I, Luder AS, Kruger N, et al. A double-blind, placebo-controlled, randomized trial of montelelukast for acute bronchiolitis. Pediatrics 122, e1249-e1255 (2008).
28. Bisgaard H. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am. J. Respir. Crit. Care Med. 167, 290-296 (2003).
29. Ventre K, Randolph A. Ribavirin for respiratory syncytial virus infection of the LRTI in infants and young children. Cochrane Database Syst. Rev. 4, CD000181 (2004).
30. McColl MD, Corser RB, Bremner J, Chopra R. Respiratory syncytial virus infection in adult BMT recipients: effective therapy with short duration nebulised ribavirin. Bone Marrow Transplant. 21, 423-425 (1998).
31. Glezen WP, Paredes A, Allison JE, et al. Risk of respiratorysyncytial virus infection for infants from low-income families in relationshipto age, sex, ethnic group, and maternal antibody level. J. Pediatr. 98, 708-715 (1981).
32. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102, 531-537 (1998).
33. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J. Pediatr. 143, 532-540 (2003).
34. American Academy of Pediatrics. Respiratory syncytial virus. In: Red Book: 2009 Report of the Committee on Infectious Diseases. 28th Edition. Pickering LK, Baker CJ, Kimberlin DW, Long SS (Eds). American Academy of Pediatrics, Elk Grove Village, IL, USA, 560-569 (2009).
35. American Academy of Pediatrics. Respiratory syncytial virus. In: Red Book: 2006 Report of the Committee on Infectious Diseases. 27th Edition. Pickering LK, Baker CJ, Long SS, McMillan JA (Eds). American Academy of Pediatrics, Elk Grove Village, IL, USA, 560-566 (2006).
36. Krilov LR, Weiner LB, Yogev R, et al. The 2009 COID recommendations for RSV prophylaxis: issues of efficacy, cost and evidence-based medicine. Pediatrics 124, 1682-1684 (2009).
37. Krilov LR, Palazzi DL, Fernandes AW, et al. Prevalence of respiratory syncytial virus (RSV) risk factors and cost implications of immunoprophylaxis to infants 32 to 35 weeks gestation for health plans in the United States. Value Health 13, 77-86 (2010).
38. Simoes EAF, Groothuis JR, Carbonell-Estrany X, et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent wheezing. J. Pediatr. 151, 34-42 (2007).
39. Malley R, DeVincenzo JP, Ramilo O, et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J. Infect. Dis. 178, 1555-1561 (1998).
40. Wu H, Pfarr DS, Johnson S, et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J. Mol. Biol. 368, 652-665 (2007).
41. Carbonell-Estrany X, Simoes EAF, Dagan R, et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 125, e35-e51 (2010).
42. Lagos R, DeViencenzo JP, Munoz A, et al. Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody when administered to RSV-infected children. Pediatr. Infect. Dis. J. 28, 835-837 (2009).
43. Olszewska W, Openshaw P. Emerging drugs for respiratory syncytial virus infection. Expert Emerg. Drugs 142, 207-217 (2009).
44. Empey KM, Peebles RS Jr, Kolls JK. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin. Infect. Dis. 50, 1258-1264 (2010).
45. Power UF. Respiratory syncytial virus (RSV) vaccines - two steps back for one leap forward. J. Clin. Virol. 41, 38-44 (2008).
46. Janssen R, Bont L, Siezen CL, et al. Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominately associated innate immune genes. J. Infect. Dis. 196, 826-834 (2007).
47. Acute Respiratory Infections (Update 2009). Initiative for vaccine research 2009 www.who.int/vaccine-research/diseases/ari/en/(Accessed 30 April 2009)
48. Centers for Disease Control and Prevention. Births and natality 2006 www.cdc.gov/nchs/fastats/births.htm (Accessed 1 July 2010)